The efficacy of anti-alpha-synuclein shRNA-MC delivered by RVG-EV to downregulate alpha-synuclein in spinal cord and intestine was evaluated using a progressive alpha-synucleinopathy mouse model based on the injection of alpha-synuclein PFFs into the striatum of normal mice. This evidence concerns the gene SNCA and synucleinopathy.